FIELD: chemical-pharmaceutical industry, proteins.
SUBSTANCE: invention concerns to cytokine-containing fused proteins showing the enhanced therapeutic index, and methods for enhancing the therapeutic index of these fused proteins. Fused proteins are able for binding with cytokine receptors of more one type expressed on cells and to bind with cells of more one type also. Except for, fused proteins possess a half-time value in blood stream of a patient as compared with that of corresponding natural cytokines.
EFFECT: improved and valuable properties of cytokines.
21 cl, 3 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTIVE AGONISTS AND ANTAGONISTS OF IL-2 | 1999 |
|
RU2235729C2 |
| ENHANCEMENT OF IMMUNE RESPONSES MEDIATED BY PROTEINS FUSED FROM ANTIBODY AND CYTOKINE BY METHOD OF COMBINED ADMINISTRATION OF ANGIOGENESIS INHIBITOR | 1999 |
|
RU2229305C2 |
| POLYVALENT MODULATORS OF REGULATORY T-CELLS | 2017 |
|
RU2769871C2 |
| MODULATION OF IL-5 AND IL-MEDIATED CELL RESPONSES | 2001 |
|
RU2280255C2 |
| VERSIONS OF ALBUMIN | 2012 |
|
RU2650784C2 |
| SINGLE-STRANDED CD40 RECEPTOR AGONIST PROTEINS | 2016 |
|
RU2745801C2 |
| HETERODIMERIC IL-15 PROTEIN AND USE THEREOF | 2014 |
|
RU2689717C2 |
| FUSED PROTEINS IL-7 | 2004 |
|
RU2369616C2 |
| FUSED PROTEIN ELICITING BIOLOGICAL ACTIVITY OF INTERFERON-ALPHA, DIMERIC FUSED PROTEIN, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF, DNA MOLECULE (VARIANTS) AND METHOD FOR TARGETING INTERFERON-ALPHA INTO LIVER TISSUE | 2000 |
|
RU2262510C9 |
| ISOLATED SOLUBLE IL-20 RECEPTOR (VARIANTS) | 2000 |
|
RU2279441C2 |
